#USA #Valencia, California #Valencia Technologies #eCoin #James D. Surek

Valencia Technologies Secures $35 Million Investment

Valencia Technologies, a leading company in the neuromodulation sector, has recently set its sights on growth through a substantial financial injection and a strategic change in leadership. On February 20, 2025, the firm announced it has garnered a strategic investment of up to $35 million from Brooks Advisory Group, a move that promises to accelerate the commercialization of its flagship product, the eCoin® system.

In line with this investment, James D. Surek—a seasoned professional with extensive experience in medical device commercialization—has been appointed as the new CEO of Valencia Technologies. Under Surek’s leadership, the company aims to capitalize on the emerging market potential for its innovative treatment methods for managing urinary incontinence.

Investment Details

This latest funding round is designed to bolster Valencia’s efforts to bring the eCoin system to a wider audience. According to Dain Black, managing partner of Brooks Management Group, the goal is to transform treatment options for bladder dysfunction significantly. The investment was approved unanimously by the Board of Directors, with Black, Surek, and Ryan Brooks joining the board alongside other established members.

Brooks Advisory Group brings not just capital but also expertise in commercialization strategies, reimbursement services, and financial planning. They are confident in their decision, highlighting Surek's exceptional track record in leading successful medical devices across various companies.

Leadership Experience of James D. Surek

James D. Surek has a rich history of driving growth within the medical device sector. His previous roles include pivotal contributions to five medical device companies, where his leadership led to successful mergers and acquisitions. Notably, during his tenure at Advanced Bionics, Surek contributed to growing revenue from nothing to over $200 million within three years, leading ultimately to a substantial acquisition by Boston Scientific Corporation for approximately $3 billion.

At Valencia Technologies, Surek will guide the advancement of the eCoin technology, aiming to hasten its commercial adoption. He expressed enthusiasm about re-entering the neuromodulation space, sharing that numerous patients have already discovered the advantages of the eCoin system.

The eCoin® System

The eCoin device is a groundbreaking solution designed to treat patients suffering from urge urinary incontinence (UUI). This coin-sized neurostimulator is implanted beneath the skin near the ankle through a minimally invasive outpatient procedure. Once implanted, the device administers regular stimulation to the tibial nerve, which is crucial for bladder control, thereby providing relief from UUI symptoms without the need for cumbersome follow-up procedures.

In clinical trials, the eCoin system showed remarkable success. It was indicated that approximately 75% of patients experienced at least a 50% reduction in their UUI episodes within a year of treatment. This simplicity of care makes eCoin a compelling alternative for patients looking for effective solutions without the burden of extensive post-procedure management.

An Industry Shift

As the healthcare landscape increasingly recognizes the need for innovative treatments, Valencia Technologies is poised for a significant shift in how urinary incontinence is managed. Dr. Jason Kim, M.D., from Stony Brook Medicine, emphasized the necessity of alternatives to prescription medications for patients living with overactive bladders. The eCoin device allows physicians to offer a straightforward, minimally invasive answer to UUI, thus improving patients’ quality of life.

Valencia Technologies is dedicated to advancing the eCoin system's reach, with the ambition of making procedures increasingly accessible in outpatient settings. The firm envisions a future where eCoin procedures are commonplace in physicians' clinics, enhancing treatment availability and comfort for patients.

Conclusion

With this strategic investment and an experienced CEO at the helm, Valencia Technologies is set to forge a path of growth and innovation in the neuromodulation market. This initiative aligns with the broader vision to redefine care standards for patients suffering from urinary incontinence, creating a brighter future for those in need of effective and convenient treatment options.